drugset / Trial / NCT05170919

Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer

NCT05170919

Phase 2 Enrolling by invitation 170 enrolled Englewood Hospital and Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether olanzapine or mirtazapine is more effective in preventing weight loss and appetite loss in cancer patients.

Timeline

Start
2022-01-20
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirtazapine Other / unclassified 15 mg
Subject Olanzapine Small molecule 2.5 mg
Subject Olanzapine Small molecule 5 mg

Indications